Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.

Original New Drug Application Approvals by US FDA (16 - 31 October 2018)

31 Oct 2018

New drug applications approved by US FDA as of 16-31 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

TALZENNA

  • Active Ingredient(s): Talazoparib
  • Strength: 0.25 mg, 1 mg
  • Dosage Form: Capsule; oral
  • Company: Pfizer Inc.
  • Approval Date: October 16, 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for  the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.
  • Approved Label: 10/16/2018(PDF)
KHAPZORY
  • Active Ingredient(s): Levoleucovorin
  • Strength: 175 mg, 300 mg
  • Dosage Form: Injectable; injection
  • Company: Spectrum Pharms
  • Approval Date: October 19, 2018
  • Submission Classification: Type 2 - New Active Ingredient
  • Indication(s): Indicated for 
    • Rescue after high-dose methotrexate therapy in patients with osteosarcoma
    • Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination. 
    • Treatment of patients with metastatic colorectal cancer in combination with fluorouracil
  • Approved Label: 10/19/2018(PDF)
XOFLUZA
  • Active Ingredient(s): Baloxavir Marboxil
  • Strength: 20 mg, 40 mg
  • Dosage Form: Tablet;oral
  • Company: Shionogi Inc
  • Approval Date: October 24, 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. 
  • Approved Label: 10/24/2018(PDF)
BIJUVA
  • Active Ingredient(s): Estradiol; Progesterone
  • Strength:  1 mg, 100 mg
  • Dosage Form: Capsule; oral
  • Company: Therapeuticsmd Inc
  • Approval Date: October 28, 2018
  • Submission Classification: Type 4 - New Combination
  • Indication(s): Indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.  
  • Approved Label: 10/28/2018(PDF)
HYRIMOZ
  • Active Ingredient(s): Adalimumab-adaz
  • Strength: 40 mg/0.8 ml
  • Dosage Form: Injectable; injection
  • Company: Sandoz Inc.
  • Approval Date: October 30, 2018
  • Submission Classification: Not Applicable
  • Indication(s): Indicated for treatment of:
    • Rheumatoid Arthritis (RA) (1.1): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. 
    • Juvenile Idiopathic Arthritis (JIA) (1.2): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 4 years of age and older. 
    • Psoriatic Arthritis (PsA) (1.3): Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA
    • Ankylosing Spondylitis (AS) (1.4): Reducing signs and symptoms in adult patients with active AS. 
    • Adult Crohn’s Disease (CD) (1.5): Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. 
    • Ulcerative Colitis (UC) (1.7): Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of HYRIMOZ has not been established in patients who have lost response to or were intolerant to TNF-blockers. 
    • Plaque Psoriasis (Ps) (1.8): The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. 
  • Approved Label: 10/30/2018(PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.